The merit of proton magnetic resonance spectroscopy in the longitudinal assessment of spinocerebellar ataxias and multiple system atrophy-cerebellar type

Hung-Chieh Chen1,2, Jiing-Feng Lin1,3, Bing-Wen Soong4,5*, Wan Yuo Guo1,3, Hsiu-Mei Wu1,3, Clayton Chi-Chang Chen1,2 and Cheng-Yen Chang1,3

Abstract

Background: Spinocerebellar ataxia (SCA) and multiple system atrophy-cerebellar type (MSA-C) often present with similar clinical manifestations in the beginning. Magnetic resonance spectroscopy (MRS) has been proved to be a useful tool to help differentiate different types of SCA and MSA-C on cross-sectional studies. However, longitudinal changes of the MRS metabolites in these subjects have never been reported. The purpose of this study was to track the longitudinal evolution of the MRS metabolites in these patients and to ascertain the correlation between clinical severity measured by Scale of the Assessment and Rating of Ataxia (SARA) and MRS metabolites.

Results: Significant reductions of NAA/Cr and NAA/Cho in the cerebellar hemispheres in all patients and lower Cho/Cr in the cerebellar hemispheres in patients with SCA2 or MSA-C were found at all times. At initial assessments, patients with MSA-C or SCA2 tended to have lower NAA/Cr and Cho/Cr in the cerebellar hemispheres than those with SCA3 or SCA6. At follow-ups, patients with SCA2 or MSA-C had a lower NAA/Cr in cerebellar hemispheres than those with SCA3 or SCA6. Patients with MSA-C had a lower NAA/Cr in the vermis and Cho/Cr in the cerebellar hemispheres than those with SCA2 at the start, and had a lower NAA/Cr in cerebellar hemispheres than those with SCA2 at follow-ups.

Conclusion: Characteristic patterns of neurodegenerative evolution were observed in patients with disparate SCAs and MSA-C using MRS and SARA. A continual impairment of neuronal integrity was observed in all groups of patients. The longitudinal changes of MRS metabolites and SARA scores were most striking in patients with SCA2 and MSA-C. Although the changes in the metabolites on MRS may still be used to help understand the pathophysiology of ataxia disorders, they are short of being a good biomarker.

Keywords: Proton MRS, SARA, Spinocerebellar ataxias, Multiple system atrophy- cerebellar type

Background

Spinocerebellar ataxia (SCA) is the most common ataxia syndrome inherited in an autosomally dominant manner and may be further categorized into 35 genotypes [1]. Multiple system atrophy-cerebellar type (MSA-C) is the most common sporadic cerebellar ataxia with a rapidly progressive course. The diagnosis of MSA-C is made according to the clinical features fitting the international consensus statement [2]. Both types of ataxia disorders present with similar clinical manifestations initially. An early and precise diagnosis is important in that it not only foretells the prognosis, allows for comprehensive genetic counseling, but also helps design the best clinical management for each patient. Scale for the Assessment and Rating of Ataxia (SARA) [3] has been validated to be a reliable semi-quantitative clinical scale of ataxia which satisfies accepted criteria of reliability and can be
used to measure the clinical severity and progression of diseases with ataxia.

Magnetic resonance spectroscopy (MRS) provides a measure of brain chemistry and has been widely used to non-invasively evaluate in vivo changes of the metabolites in the brain. Creatine (Cr) provides a measure of energy stores in the brain. It is very stable and is usually used as a reference for comparison. N-acetylaspartate (NAA) is a marker for neuronal integrity or volume [4,5] and a reduction of NAA denotes a pathological process that adversely affects neuronal integrity [6-9]. Choline (Cho) is a measure of cellular turnover, reflecting the content of cytotoxic glycerolphosphocholine and phosphocholine and representing the products of membrane phosphotidylcholine breakdown, precursors of choline and acetylcholine synthesis [10]. A reduction in Cho reflects impairment in the production of cell membranes, the precursor of neurotransmitter acetylcholine and acetylcholine itself. NAA/Cho has been used as a marker for cerebral metabolism [6,11,12].

In the literature, there have been several cross-sectional studies on the changes of MRS metabolites in patients with SCA or MSA-C [13-18], including one from our group reporting the differences of MRS metabolites between SCAs and MSA-C [18]. MRS has also been used to longitudinally follow the progression of other central nervous system disorders, such as dementia [19], mania [20], traumatic brain injury [21] and HIV encephalopathies [22]. The changes of metabolites in MRS faithfully correlated with the changes in clinical severity.

In this paper, we compare the longitudinal changes of MRS metabolites in the brain and SARA scores in patients with disparate types of SCAs and MSA-C and ascertain their correlations.

### Results

The patients with SCA3 were younger than those with SCA2 and MSA-C (Table 1). Otherwise, there was no significant difference between patient groups in terms of disease duration, SARA scores at the time when the first or the second MRS assessment was performed, or the time interval in between two assessments.

The MRS of patients with different SCAs and MSA-C were demonstrated in Figure 1.

#### Patients with MSA-C

In patients with MSA-C, the NAA/Cr, Cho/Cr and NAA/Cho in both the cerebellar hemispheres and vermis were significantly reduced ($p < 0.001$) at both MRS assessments, as compared with those of the healthy controls (Table 2).

#### Patients with SCA

In all types of SCAs studied, the NAA/Cr in the cerebellar hemispheres and vermis and NAA/Cho in the cerebellar hemispheres were significantly reduced ($p < 0.05$) at both assessments (Table 2).

In patients with SCA2, the Cho/Cr in the cerebellar hemispheres was significantly reduced ($p < 0.05$) at both MRS assessments (Table 2) and in the vermis only at the second MRS assessment, as compared with the healthy controls.

In patients with SCA3, NAA/Cho in the vermis appeared consistently reduced and Cho/Cr in the cerebellar hemisphere became significantly reduced than healthy controls at 2nd MRS assessment ($p < 0.05$). (Table 2) In patients with SCA6, NAA/Cho appeared significantly reduced in the vermis at initial assessment. ($p = 0.024$) (Table 2).

### Table 1 Demographic features of the subjects

| Number of patients | Age (years) | First MRS assessment | Second MRS assessment |
|--------------------|-------------|----------------------|-----------------------|
|                    |             | Disease duration (months) | SARA scores          | Disease duration (months) | SARA scores | Interval in between 2 MRS assessments (months) |
| $p^*$              | 0.03        | 0.326                | 0.195                | 0.736                  | 0.114       | 0.680 |
| SCA2               | 5           | 60.6 ± 11.1$^*$      | 3.7 ± 3.03           | 8.4 ± 3.13             | 43.0 ± 15.47 | 17.13 ± 7.1 | 38.63 ± 13.21 |
| SCA3               | 18          | 46.3 ± 10.0$^*$      | 6.14 ± 3.96          | 10.97 ± 6.28           | 49.91 ± 23.82 | 15.28 ± 5.23 | 43.78 ± 21.74 |
| SCA6               | 3           | 59.0 ± 13.9          | 6.83 ± 2.36          | 12.5 ± 2.65            | 42.25 ± 15.2 | 19.0 ± 1.41 | 34.5 ± 17.68 |
| MSA-C              | 12          | 60.6 ± 6.1$^*$       | 4.25 ± 2.20          | 15.29 ± 6.71           | 38.7 ± 12.33 | 22.35 ± 7.02 | 34.3 ± 12.82 |
| HC                 | 44          | 51.1 ± 17.9          | –                     | –                      | –           | –           |

SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA: Multiple system atrophy- cerebellar type; HC: Healthy controls.

$^*$The patients with SCA 3 were significantly younger than those with SCA2 ($p = 0.014$) or MSA-C ($p = 0.001$).

$^*$Kruskal-Wallis test.
Figure 1 The MR spectroscopy of the patients at the initial (upper) and follow-up (lower) assessments. (A) healthy controls, (B) SCA2, (C) SCA3, (D) SCA6 and (E) MSA-C.
Table 2 Comparison of $^1$H MRS metabolites between the patients with SCA, MSA-C and controls and between 2 assessments in each group

| Metabolites on the 1st MRS | The 1st MRS vs. controls | The 2nd MRS vs. controls | 1st vs. 2nd MRS |
|---------------------------|--------------------------|--------------------------|-----------------|
| **Cerebellar hemispheres** |                          |                          |                 |
| NAA/Cr                    |                          |                          |                 |
| SCA2                      | 0.65 ± 0.10              | 0.72 ± 0.06              | 0.000           | 0.000           | 0.113 |
| SCA3                      | 0.88 ± 0.10              | 0.85 ± 0.08              | 0.000           | 0.000           | 0.073 |
| SCA6                      | 0.83 ± 0.07              | 0.87 ± 0.08              | 0.001           | 0.014           | 0.440 |
| MSA-C                     | 0.58 ± 0.14              | 0.62 ± 0.23              | 0.000           | 0.000           | 0.331 |
| HC                        | 1.00 ± 0.12              | -                        | -               | -               | -     |
| Cho/Cr                    |                          |                          |                 |
| SCA2                      | 0.58 ± 0.07              | 0.62 ± 0.05              | 0.001           | 0.019           | 0.031 |
| SCA3                      | 0.68 ± 0.09              | 0.65 ± 0.08              | 0.392           | 0.027           | 0.098 |
| SCA6                      | 0.69 ± 0.08              | 0.65 ± 0.04              | 0.710           | 0.279           | 0.116 |
| MSA-C                     | 0.50 ± 0.10              | 0.52 ± 0.14              | 0.000           | 0.000           | 0.955 |
| HC                        | 0.70 ± 0.09              | -                        | -               | -               | -     |
| NAA/Cho                   |                          |                          |                 |
| SCA2                      | 1.14 ± 0.27              | 1.16 ± 0.16              | 0.004           | 0.000           | 0.796 |
| SCA3                      | 1.30 ± 0.17              | 1.31 ± 0.15              | 0.000           | 0.001           | 0.768 |
| SCA6                      | 1.23 ± 0.15              | 1.34 ± 0.10              | 0.008           | 0.174           | 0.113 |
| MSA-C                     | 1.17 ± 0.29              | 1.21 ± 0.28              | 0.000           | 0.000           | 0.263 |
| HC                        | 1.45 ± 0.19              | -                        | -               | -               | -     |
| **Vermis**                |                          |                          |                 |
| NAA/Cr                    |                          |                          |                 |
| SCA2                      | 0.74 ± 0.05              | 0.70 ± 0.09              | 0.000           | 0.003           | 0.421 |
| SCA3                      | 0.82 ± 0.07              | 0.80 ± 0.08              | 0.002           | 0.000           | 0.205 |
| SCA6                      | 0.79 ± 0.06              | 0.76 ± 0.06              | 0.024           | 0.043           | 0.126 |
| MSA-C                     | 0.63 ± 0.08              | 0.64 ± 0.08              | 0.000           | 0.000           | 0.966 |
| HC                        | 0.90 ± 0.11              | -                        | -               | -               | -     |
| Cho/Cr                    |                          |                          |                 |
| SCA2                      | 0.61 ± 0.08              | 0.55 ± 0.06              | 0.062           | 0.003           | 0.233 |
| SCA3                      | 0.66 ± 0.07              | 0.65 ± 0.08              | 0.433           | 0.194           | 0.910 |
| SCA6                      | 0.70 ± 0.03              | 0.65 ± 0.06              | 0.494           | 0.463           | 0.451 |
| MSA-C                     | 0.54 ± 0.06              | 0.50 ± 0.11              | 0.000           | 0.000           | 0.178 |
| HC                        | 0.68 ± 0.07              | -                        | -               | -               | -     |
| NAA/Cho                   |                          |                          |                 |
| SCA2                      | 1.22 ± 0.19              | 1.28 ± 0.07              | 0.174           | 0.380           | 0.833 |
| SCA3                      | 1.25 ± 0.13              | 1.22 ± 0.13              | 0.072           | 0.002           | 0.170 |
| SCA6                      | 1.13 ± 0.10              | 1.17 ± 0.02              | 0.024           | 0.065           | 0.766 |
| MSA-C                     | 1.16 ± 0.08              | 1.31 ± 0.24              | 0.000           | 0.991           | 0.083 |
| HC                        | 1.32 ± 0.18              | -                        | -               | -               | -     |

**SCA2**: Spinocerebellar ataxia type 2; **SCA3**: Spinocerebellar ataxia type 3; **SCA6**: Spinocerebellar ataxia type 6; **MSA-C**: Multiple system atrophy-cerebellar type; **HC**: Healthy controls.

*Mann-Whitney test, $p$ value.

*Pair-t test, $p$ value.

**Comparison between patients with different types of SCA and MSA-C**

At the first MRS assessment (Table 3), patients with MSA-C had a significantly lower NAA/Cr and Cho/Cr in the cerebellar hemispheres and vermis than those with SCA3 or SCA6, and a lower NAA/Cho in the cerebellar hemispheres than those with SCA3. Furthermore, patients with SCA2 had a significantly lower NAA/Cr
and Cho/Cr in the cerebellar hemispheres than those with SCA3 or SCA6.

At the second MRS assessment (Table 4), patients with MSA-C still had lower NAA/Cr, Cho/Cr in the cerebellar hemispheres and vermis than those with SCA3 and lower NAA/Cr in the cerebellar hemispheres than those with SCA2 and SCA6. Patients with SCA2 continued to have lower NAA/Cr in the cerebellar hemispheres than those with SCA3 or SCA6.

Longitudinal changes in the MRS metabolites

There was no significant difference in the MRS metabolites between initial and follow up assessments in the study groups (Table 2), except for an increase of Cho/Cr with time in the cerebellar hemispheres in patients with SCA2 (p = 0.031) (Table 2). Furthermore, there was no difference in the monthly changes of metabolites between different groups of patients (Table 5 and Figure 2).

Longitudinal changes in the SARA scores

There were significant increases of SARA scores with time in patients with SCA2 (p = 0.031), SCA3 (p < 0.001) and MSA-C (p < 0.001), but not in SCA6 (p = 0.318) (Table 6). Moreover, if we compared the changes of SARA on a monthly basis, patients with MSA-C and SCA2 stood out and seemed to have a faster progression than those with SCA3 or SCA6 (Table 6, Figure 2G), although the difference had not reached a statistical significance.

The correlation between the changes of MRS metabolites and SARA scores

The changes of NAA/Cr (R = -0.332, P < 0.001 in the cerebellar hemispheres; R = -0.521, P < 0.001 in the vermis) and Cho/Cr (R = -0.380; P < 0.001 in the cerebellar hemispheres; R = -0.529, P < 0.001 in the vermis) were inversely correlated with the changes of SARA scores (Figure 3).

Discussion

To our knowledge, this is the first study designed to evaluate the longitudinal changes of metabolites on MRS in conjunction with the clinical severity measured with SARA in patients with ataxia syndromes. Our study has several strengths. First, the same MR instrument and study protocol were used throughout. Second, the clinical severity was evaluated uniformly by a single board-certified neurologist who is experienced in evaluating ataxia with the same valid assessment scale, SARA. Third, the disease duration and clinical severity at two assessments were similar across different diseases.

In this study, a continual impairment in neuronal integrity, as indicated by the reduction in NAA/Cr in the

Table 3 The differences in MRS metabolites between patient groups at the 1st MRS assessment

| Disease | NAA/Cr | SCA3 | SCA6 | MSA-C |
|---------|--------|------|------|-------|
| Cerebellar hemispheres | |
| NAA/Cr | SCA2 0.000 | 0.004 | 0.155 |
| SCA3 - | 0.356 | 0.000 |
| SCA6 - | - | 0.000 |
| Cho/Cr | SCA2 0.010 | 0.039 | 0.035 |
| SCA3 - | 0.985 | 0.000 |
| SCA6 - | - | 0.002 |
| NAA/Cho | SCA2 0.236 | 0.060 | 0.743 |
| SCA3 - | 0.356 | 0.018 |
| SCA6 - | - | 0.401 |
| Vermis | |
| NAA/Cr | SCA2 0.037 | 0.297 | 0.013 |
| SCA3 - | 0.487 | 0.000 |
| SCA6 - | - | 0.024 |
| Cho/Cr | SCA2 0.256 | 0.180 | 0.064 |
| SCA3 - | 0.252 | 0.001 |
| SCA6 - | - | 0.011 |
| NAA/Cho | SCA2 0.730 | 0.456 | 0.493 |
| SCA3 - | 0.158 | 0.092 |
| SCA6 - | - | 0.665 |

SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy-cerebellar type.
*Mann-Whitney test, p-value.

Table 4 The differences in MRS metabolites between patient groups at 2nd MRS assessment

| Disease | NAA/Cr | SCA3* | SCA6* | MSA-C* |
|---------|--------|-------|-------|--------|
| Cerebellar hemispheres | |
| NAA/Cr | SCA2 0.001 | 0.014 | 0.017 |
| SCA3 - | 0.538 | 0.000 |
| SCA6 - | - | 0.022 |
| Cho/Cr | SCA2 0.197 | 0.393 | 0.055 |
| SCA3 - | 0.979 | 0.001 |
| SCA6 - | - | 0.067 |
| NAA/Cho | SCA2 0.026 | 0.089 | 0.617 |
| SCA3 - | 0.456 | 0.077 |
| SCA6 - | - | 0.202 |
| Vermis | |
| NAA/Cr | SCA2 0.064 | 0.355 | 0.356 |
| SCA3 - | 0.526 | 0.000 |
| SCA6 - | - | 0.085 |
| Cho/Cr | SCA2 0.017 | 0.064 | 0.480 |
| SCA3 - | 0.880 | 0.003 |
| SCA6 - | - | 0.133 |
| NAA/Cho | SCA2 0.484 | 0.165 | 0.777 |
| SCA3 - | 0.233 | 0.202 |
| SCA6 - | - | 0.390 |

SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy-cerebellar type.
*Mann-Whitney test, p value.
cerebellar hemispheres and vermis (Table 2), at both initial and follow-up assessments was found in all groups of patients. Over the timespan of 2–4 years, not much difference in MRS metabolites was observed between two MRS assessments (Table 2) in all SCA subgroups and MSA-C, suggesting that MRS metabolites are not sensitive enough markers to track the changes in cerebellar metabolism over the limited time span of follow-up (Table 2). Further study with larger sample sizes might be needed to validate these observations. On the other hand, SARA scores faithfully reflected the deterioration in severity of SCA2, SCA3 and MSA-C over the time span (Table 6), implicating that SARA qualifies as a more sensitive marker to gauge the progression of cerebellar ataxias. Nevertheless, the changes of NAA/Cr and Cho/Cr in the cerebellar hemispheres and vermis somehow still inversely correlated with the changes in SARA scores. The evolution of different metabolites on MRS could still, to a certain degree, help understand the pathophysiology of the disease.

**MSA-C**

In general, patients with MSA-C tended to have a worse neuronal integrity and less production of cell membranes than those with SCA3 or SCA6 at the first MRS assessment (Tables 2 and 3). With time, the differences remained similar at follow-ups (Table 4), suggesting a persistent and more severe disruption in the neuronal and membrane integrity in MSA-C. MSA-C is a rapidly progressive neurodegenerative disease manifesting ataxia and autonomic dysfunction [23]. Our previous cross-sectional study in patients with MSA-C also corroborated these observations [18].

MSA-C and SCA2 are two relentlessly and rapidly progressive diseases manifesting ataxia with neuronal drop-outs and impairment of membrane synthesis. Lactate peak and myo-inositol were previously proposed to be indicators to differentiate SCA2 from MSA-C [14–16]. In this study, we found that, at the early stage of the diseases, the MRS features were similar between MSA-C and SCA2. As disease progressed, the different speed of changes in Cho/Cr and NAA/Cr in the cerebellar hemispheres might help differentiate MSA-C from SCA2 (Table 4).

**SCA**

In line with previous reports [15,16], patients with SCA2 have a more severe impairment in neuronal integrity, given the lower NAA/Cr in the cerebellar hemispheres than those with SCA3 or SCA6 at the start and at the follow-up assessment, even being of similar clinical severity (Tables 2, 3 and 4). The SARA scores increased significantly in SCA2 and SCA3 but not in SCA6 during the period of follow up (Tables 1 and 6). Although there was little difference in the monthly changes of SARA scores between subtypes of SCAs, the change was still higher in SCA2 (Table 6). Pathological studies in the past have revealed, in SCA2, a marked loss of Purkinje cells in the cerebellar cortex and a loss of myelinated fibers in the cerebellar peduncles and white matter, sparing the dentate nucleus, and the neuronal degeneration preceded the onset of clinical symptoms [24]. While a prominent spinopontine degeneration with a relative sparing of the olivocerebellar regions in SCA3 [25] and a pure cerebellar degeneration with a loss of Purkinje cells in the cerebellar cortex in SCA6 [26,27] were observed. The synaptic loss in the cerebellum and brainstem is most severe in SCA2 [28,29]. The MRS changes observed by us are corroborated by the pathological changes.

The disease progression reflected by the monthly changes of SARA scores was most severe in SCA2, MSA-C, followed by SCA3 and SCA6. Similar results have been documented in our earlier report [30].

**Interval changes**

Progressive reduction in the cerebellar volume, correlating with disease duration and age, has been documented in patients with MSA-C [31], SCA2 [32], SCA3 [33] and SCA6 [34]. In SCA2, the presence of pre-symptomatic region-specific atrophy was observed and a possible developmental component to the pathomechanisms was

---

Table 5 The monthly changes of MRS metabolites in different groups of patients†

|                | Cerebellar hemispheres | Vermis          |
|----------------|------------------------|-----------------|
|                | NAA/Cr                 | Cho/Cr | NAA/Cho | NAA/Cr | Cho/Cr | NAA/Cho |
| p*            | 0.471                  | 0.168 | 0.261 | 0.693 | 0.269 | 0.273 |
| SCA2          | 0.09 ± 0.17            | 0.13 ± 0.14 | −0.08 ± 0.28 | −0.25 ± 0.53 | −0.18 ± 0.23 | −0.08 ± 0.68 |
| SCA3          | −0.04 ± 0.22           | −0.04 ± 0.26 | 0.01 ± 0.61 | −0.07 ± 0.20 | 0.05 ± 0.21 | −0.22 ± 0.37 |
| SCA6          | 0.06 ± 0.22            | −0.11 ± 0.16 | 0.27 ± 0.44 | −0.18 ± 0.13 | −0.16 ± 0.16 | 0.00 ± 0.45 |
| MSA-C         | 0.14 ± 0.59            | 0.02 ± 0.37 | 0.33 ± 1.14 | 0.03 ± 0.32 | −0.14 ± 0.36 | 0.51 ± 0.86 |

SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy- cerebellar type.

†Data are presented as 100X MRS ratios.

*Kruskal-Wallis test.
once proposed [32]. This is consistent with the early MRS changes in SCA2 when the clinical severity represented by SARA scores is still low and disease duration remains short.

The limitations of this study are, first, the sizes of the patients were relatively small, especially in SCA2 and SCA6. The small patient numbers could be the reason contributing to the lack of significance in disease

**Figure 2 Monthly changes of the MRS metabolites and the SARA scores.** (A) NAA/Cr in the cerebellar hemispheres, (B) Cho/Cr in the cerebellar hemispheres, (C) NAA/Cho in the cerebellar hemispheres, (D) NAA/Cr in the vermis, (E) Cho/Cr in the vermis, (F) NAA/Cho in the vermis. (G) Changes of total SARA scores.
duration between groups. We tried to minimize these heterogeneities by recruiting only patients who had their first MRS examination at a disease duration less than 12 months. Furthermore, the MRS metabolites from both cerebellar hemispheres were averaged for the ease of analyses, thus the data of MRS from the cerebellar hemispheres should actually be twice as many as those from the vermis. Hence, the reason that some differences of MRS in patient groups were observed only in the cerebellar hemispheres, but not in the vermis, could likely be attributed to the limited patient numbers. Third, we only focused on the metabolites in the cerebellar hemispheres and vermis. Fourth, we only correlated the metabolites on MRS with total SARA scores.

### Table 6 The monthly changes of SARA scores in different groups of patients

| Group   | SARA score at the 1st assessment | SARA score at the 2nd assessment | 1st vs. 2nd SARA scores | Monthly changes of SARA |
|---------|---------------------------------|----------------------------------|-------------------------|-------------------------|
| p       | 0.195                           | 0.114                            | 0.343                   |                         |
| SAC2    | 8.4 ± 3.13                      | 17.13 ± 7.1                      | 0.031                   | 0.31 ± 0.24             |
| SAC3    | 10.97 ± 6.28                    | 15.28 ± 5.23                     | 0.000                   | 0.15 ± 0.10             |
| SAC6    | 12.5 ± 2.65                     | 19.0 ± 1.41                      | 0.318                   | 0.15 ± 0.05             |
| MSA-C   | 15.29 ± 6.71                    | 22.35 ± 7.02                     | 0.000                   | 0.26 ± 0.18             |

*Kruskal-Wallis test.

Pair-t test, p value.

Figure 3 The correlation between SARA and MRS metabolites. (A) NAA/Cr in the cerebellar hemispheres vs. SARA, (B) Cho/Cr in the cerebellar hemispheres vs. SARA, (C) NAA/Cr in the vermis vs. SARA and (D) Cho/Cr in the vermis vs. SARA.
The rates of progression in different compartments of SARA might be different [30]. Further studies with MRS in a larger cohort, addressing also the changes of metabolites in the other regions of the brain while correlating the changes between MRS metabolites and different compartments of SARA, would be desirable to help unravel the pathophysiology of the SCAs and MSA-C.

Conclusion
Different patterns of neurodegeneration with impairment in neuronal integrity and detective membrane activities were observed in patients with SCAs and MSA-C in this longitudinal study. Although the changes on MRS negatively correlated with clinical severity (Figure 2), MRS does not seem to be a sensitive marker to assess the progress of ataxia syndromes. Nevertheless, the longitudinal changes of MRS and SARA scores in SCA2, SCA3 and MSA-C were different, both in the beginning and on the follow-up’s. Changes in MRS metabolites may still be used to help understand the underlying pathophysiology of ataxia disorders.

Methods
Patients and controls
This study was approved by the Institutional Review Board of Taipei Veterans General Hospital, Taipei, Taiwan. Patients who had undergone SARA and MR spectroscopy at least twice over a period of 10 years were enlisted. The interval between evaluations with SARA and the MR spectroscopy must be approximately within 3 months. From March 2004 to January 2014, a total of 47 patients with either one of the SCAs or MSA-C were studied sequentially in the afore-mentioned manner. Among them, 38 patients had their first MRS assessment with a disease duration less than 12 months and the follow-up MRS after one year. Among them, 5 were molecularly identified to be SCA2, 18 SCA3, and 3 SCA6. Twelve patients met the criteria of MSA-C. Forty-four healthy individuals without any history of neurological diseases served as controls. The MRS features in the basal ganglion were validated from the MRS analyses to ensure high quality.

Images and spectroscopic acquisition
Brain MRI and MRS were performed using a 1.5-T system (Signa EXCITE, GE Medical Systems, Milwaukee, WI). The MRI protocol consisted of an axial T1-weighted three-dimensional fast-spoiled gradient recalled acquisition in steady state images (TR 8.58 msec, TE 3.62 msec, inversion time [TI] 400 msec, voxel resolution 0.75X0.75X1.5 mm³) and an axial T2 fast spin-echo sequence [TR 4000 msec, TE 256.5 msec, voxel resolution 348X512]. After MR imaging, proton MRS was recorded in the cerebellar hemispheres and vermis by using single-voxel stimulated echo acquisition mode sequence (3000/15/13.7/96 [TR/TE/mixing time/excitations], spectral width = 2500 Hz, number of points = 2048, voxel resolution = 2 cm × 2 cm × 2 cm). The voxel of interest (VOI) in each subject was placed in a uniform manner by the same investigator (JFL). Care was taken to avoid cerebrospinal fluid space within the VOIs. The peak areas for N-acetyl aspartate (NAA) at 2.02 parts per million (ppm), Creatine (Cr) at 3.03 ppm, and Choline (Cho) at 3.22 ppm were measured using the Functool provided by the MR company (GE XVi, Milwaukee, WI). Peak integral values were expressed relative to the Cr peak. Metabolite intensity ratios were automatically calculated at the end of each single voxel acquisition including NAA/Cr and Cho/Cr. The NAA/Cho ratio was also calculated for comparison. MRS results with full width at half maximum (FWHM) > 6 Hz were disqualified from the MRS analyses to ensure high quality.

Statistical analyses
Comparisons of the age at examination between the patient groups and healthy controls and comparison of the disease duration and the SARA scores at first and second evaluations between the patient groups were performed using nonparametric analyses (Kruskal-Wallis H test) given that some of the sample sizes were small and the assumption of a Gaussian distribution was not appropriate. Similarly, given the non-Gaussian distribution of the MRS parameters, comparison of the metabolites on MRS (NAA/Cr, Cho/Cr and NAA/Cho in the cerebellar hemispheres or vermis) between different groups of patients and healthy controls, between patients of disparate types of SCA and MSA-C, between patients with different types of SCA at initial and follow-up MRS assessments, and comparison of the monthly changes of metabolites on MRS and SARA scores were all performed using the nonparametric Mann–Whitney U-test. The interval changes of metabolites on MRS and SARA scores were evaluated by pair-t test. The correlation between metabolites on MRS and SARA scores was assessed with Pearson’s correlation coefficient. Differences were considered significant at p < 0.05. Data are given as mean ± standard deviation.

Abbreviations
SCA: Spinocerebellar ataxia; MSA-C: Multiple system atrophy-cerebellar type; MRS: Magnetic resonance spectroscopy; SARA: Scale of the Assessment and Rating of Ataxia; Cr: Creatine; NAA: N-acetylaspartate; Cho: Choline; VOI: Voxel of interest.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JFL and BWS conceived the work; HCC, JFL, BWS, WYG, HMW completed all the data collection; HCC and BWS analysed the data; HCC and BWS wrote the manuscript and have both read and approved the final manuscript.
References

1. Jayadev S, Bird TD: Hereditary ataxias: overview. Genet Med 2013, 15:673–683.
2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Golosso C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppl K, Vasilheth M: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670–676.
3. Schmitz-Hubrich T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowitz M, Ribai P, Rola R, Schols J, Smyrnakis S, van de Warrenburg BP, Durr A, Klockgether T, Farcom NU: Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006, 66:1717–1720.
4. Urenjak J, Williams SR, Gadian DG: Noble for Proton magnetic resonance spectroscopy unambiguously identifies different neural cell histopathology correlates of spectral changes. J Neurosci 2006, 193:109–115.
5. Oppenheim SM, Bryan RN, Conturo TE, Soher BJ, Preziosi TJ, Barker PB: Proton magnetic resonance spectroscopy and gadolinium-DTPA perfusion imaging of asymptomatic MR white matter lesions. Radiology 1995, 33:61–68.
6. Miller BL: A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine, and choline. NMR Biomed 1991, 4:47–52.
7. Van der Grond J, Balm R, Kappelle LJ, Eikelboom BC, Mail WP: Cerebral metabolism of patients with senility or occlusion of the internal carotid artery, a 1H-MR spectroscopic imaging study. Stroke 1995, 26:822–828.
8. Ng TC, Connors YG, Xue M, So R, Majors A, Kolek H, Luders H, Modic M: Temporal lobe epilepsy: presurgical localization with computerized chemical shift imaging. Radiology 1994, 193:465–472.
9. Ross BM, Eder K, Moszczyńska A, Maralais N, Lamarche J, Ang L, Pandolfo M, Rouleau G, Kirchgessner M, Kish SJ: Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar ataxia type-1. Mov Disord 2000, 15:294–300.
10. Boesch SM, Schocke M, Burk K, Kloslo I, Pernish P, Forrai I, Achter FT, Poewe W, Felser S: Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6. J Magn Reson Imaging 2001, 13:553–559.
11. Boesch SM, Wolf C, Seppl K, Felser S, Wenning GK, Schocke M: Differentiation of SC2A from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2007, 25:564–569.